---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-022103"
form_type: "8-K"
ticker: "MGRX"
cik: "0001938046"
company_name: "MANGOCEUTICALS, INC."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:37:34.913626+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Mangoceuticals partners with Lilly and Novo Nordisk for GLP-1 access programs; $99/month membership

## Summary
- Launches MangoRx Direct and PeachesRx Direct providing access to Zepbound (Eli Lilly) and Wegovy (Novo Nordisk) via telehealth.
- Membership fee $99/month includes unlimited virtual visits, progress tracking, lifestyle coaching; GLP-1 meds from $499/month cash-pay.
- No insurance required; prescriptions fulfilled via LillyDirect Self Pay, NovoCare Pharmacy, or local pharmacies.
- Company highlights White House deal lowering government GLP-1 pricing to $245/month and $50 Medicare copays from mid-2026.
- CEO Jacob Cohen states program targets 42% of U.S. adults with obesity, aiming to make treatment simple and sustainable.

## SEC filing metadata
- accession: 0001493152-25-022103
- form_type: 8-K
- ticker: MGRX
- cik: 0001938046
- company_name: MANGOCEUTICALS, INC.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1938046/000149315225022103/0001493152-25-022103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1938046/000149315225022103/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-022103
- JSON: https://secwatch.observer/filing/0001493152-25-022103.json
- Plain text: https://secwatch.observer/filing/0001493152-25-022103.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.